{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:16Z","timestamp":1790612116742,"version":"4.1.0"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ijcard.2016.09.075","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T02:00:51Z","timestamp":1474855251000},"page":"184-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":159,"special_numbering":"C","title":["Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Stulc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25 Pt B","key":"10.1016\/j.ijcard.2016.09.075_bb0005","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.075_bb0010","doi-asserted-by":"crossref","first-page":"1168.e1","DOI":"10.1016\/j.recesp.2011.09.014","article-title":"[ESC\/EAS guidelines for the management of dyslipidaemias]","volume":"64","author":"Reiner","year":"2011","journal-title":"Rev. Esp. Cardiol."},{"issue":"21","key":"10.1016\/j.ijcard.2016.09.075_bb0015","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1001\/archinte.166.21.2307","article-title":"Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials","volume":"166","author":"Thavendiranathan","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.075_bb0020","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","article-title":"Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes","volume":"57","author":"Cheung","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9753","key":"10.1016\/j.ijcard.2016.09.075_bb0025","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"issue":"9841","key":"10.1016\/j.ijcard.2016.09.075_bb0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists","year":"2012","journal-title":"Lancet"},{"issue":"9976","key":"10.1016\/j.ijcard.2016.09.075_bb0035","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists","year":"2015","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ijcard.2016.09.075_bb0040","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.jacc.2015.08.042","article-title":"Trends in the use of nonstatin lipid-lowering therapy among patients with coronary heart disease: a retrospective cohort study in the Medicare population 2007 to 2011","volume":"66","author":"Bittner","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.075_bb0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","article-title":"Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease","volume":"65","author":"Rosenson","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0050","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5694\/j.1326-5377.1996.tb94138.x","article-title":"Apparent discontinuation rates in patients prescribed lipid-lowering drugs","volume":"164","author":"Simons","year":"1996","journal-title":"Med. J. Aust."},{"issue":"18","key":"10.1016\/j.ijcard.2016.09.075_bb0055","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.279.18.1458","article-title":"Persistence of use of lipid-lowering medications: a cross-national study","volume":"279","author":"Avorn","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0060","first-page":"485","article-title":"Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study","volume":"21","author":"Blackburn","year":"2005","journal-title":"Can. J. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.075_bb0065","first-page":"306","article-title":"Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population","volume":"11","author":"Schultz","year":"2005","journal-title":"Am. J. Manag. Care"},{"issue":"10","key":"10.1016\/j.ijcard.2016.09.075_bb0070","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","article-title":"Predictors of adherence with antihypertensive and lipid-lowering therapy","volume":"165","author":"Chapman","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0738-3991(98)00107-4","article-title":"The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence","volume":"37","author":"Svarstad","year":"1999","journal-title":"Patient Educ. Couns."},{"issue":"11","key":"10.1016\/j.ijcard.2016.09.075_bb0080","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1345\/aph.1K209","article-title":"Factors related to adherence to statin therapy","volume":"41","author":"McGinnis","year":"2007","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance \u2014 an attempt at a unified definition. Position paper from an international lipid expert panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch. Med. Sci."},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.075_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11883-015-0552-3","article-title":"Statin intolerance: the clinician's perspective","volume":"17","author":"Stulc","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"issue":"3 Suppl.","key":"10.1016\/j.ijcard.2016.09.075_bb0095","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2014.03.003","article-title":"NLA task force on statin safety\u20142014 update","volume":"8","author":"Jacobson","year":"2014","journal-title":"J. Clin. Lipidol."},{"issue":"10","key":"10.1016\/j.ijcard.2016.09.075_bb0100","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"13","key":"10.1016\/j.ijcard.2016.09.075_bb0105","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1161\/CIRCULATIONAHA.114.013189","article-title":"Cardiology patient page. Statin intolerance","volume":"131","author":"Fitchett","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.09.075_bb0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.atherosclerosis.2015.12.015","article-title":"Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey","volume":"245","author":"Hovingh","year":"2016","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0120","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2125.2006.02828.x","article-title":"Impact of adherence to statins on coronary artery disease in primary prevention","volume":"63","author":"Bouchard","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.ijcard.2016.09.075_bb0125","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","article-title":"Predictors of nonadherence to statins: a systematic review and meta-analysis","volume":"44","author":"Mann","year":"2010","journal-title":"Ann. Pharmacother."},{"issue":"11","key":"10.1016\/j.ijcard.2016.09.075_bb0130","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s12325-015-0264-7","article-title":"A retrospective study to examine healthcare costs related to cardiovascular events in individuals with hyperlipidemia","volume":"32","author":"Henk","year":"2015","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.075_bb0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/ebmed-2015-110253","article-title":"Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome","volume":"20","author":"Toth","year":"2015","journal-title":"Evid. Based Med."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MAJ.0000000000000292","article-title":"Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease","volume":"348","author":"Gamboa","year":"2014","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries \u2014 findings from the EUROASPIRE IV survey","volume":"246","author":"Reiner","year":"2016","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.075_bb0150","first-page":"1428","article-title":"Therapeutic inertia in the outpatient management of dyslipidemia in patients with ischemic heart disease. The inertia study","volume":"63","author":"Lazaro","year":"2010","journal-title":"Rev. Esp. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcard.2016.09.075_bb0155","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.075_bb0160","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.HYP.0000200702.76436.4b","article-title":"Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals","volume":"47","author":"Okonofua","year":"2006","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.075_bb0165","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2337\/diacare.28.3.600","article-title":"Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?","volume":"28","author":"Shah","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2016.09.075_bb0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12875-015-0221-1","article-title":"Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium","volume":"16","author":"Aujoulat","year":"2015","journal-title":"BMC Fam. Pract."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.075_bb0175","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/dme.12592","article-title":"Acknowledging and allocating responsibility for clinical inertia in the management of type 2 diabetes in primary care: a qualitative study","volume":"32","author":"Zafar","year":"2015","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12944-015-0037-y","article-title":"Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey","volume":"14","author":"Krempf","year":"2015","journal-title":"Lipids Health Dis."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0185","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.atherosclerosis.2010.09.014","article-title":"Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey","volume":"213","author":"Reiner","year":"2010","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.ijcard.2016.09.075_bb0190","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7812\/TPP\/09-090","article-title":"Patients' perspectives on nonadherence to statin therapy: a focus-group study","volume":"14","author":"Fung","year":"2010","journal-title":"Perm. J."},{"issue":"9","key":"10.1016\/j.ijcard.2016.09.075_bb0200","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/clc.22432","article-title":"Insights into statin intolerance","volume":"38","author":"Kopecky","year":"2015","journal-title":"Clin. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12944-015-0169-0","article-title":"Lipids, blood pressure and kidney update 2015","volume":"14","author":"Banach","year":"2015","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0210","doi-asserted-by":"crossref","first-page":"g2940","DOI":"10.1136\/bmj.g2940","article-title":"Meta-analysis of side effects of statins shows need for trial transparency","volume":"348","author":"Goldacre","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2016.09.075_bb0215","article-title":"Statin tolerability: in defence of placebo-controlled trials","author":"Tobert","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can. J. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0225","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.clnu.2015.09.007","article-title":"A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations","volume":"35","author":"Serban","year":"2016","journal-title":"Clin. Nutr."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0230","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5114\/aoms.2015.50960","article-title":"Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Ursoniu","year":"2015","journal-title":"Arch. Med. Sci."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0235","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nut.2015.06.009","article-title":"Effect of garlic on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"32","author":"Sahebkar","year":"2016","journal-title":"Nutrition"},{"key":"10.1016\/j.ijcard.2016.09.075_bb0240","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DMSO.S11244","article-title":"Treating statin-intolerant patients","volume":"4","author":"Arca","year":"2011","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2012.05.007","volume":"223","author":"Perk","year":"2012","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.075_bb0250","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.107.708388","article-title":"Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment","volume":"117","author":"Krauss","year":"2008","journal-title":"Circulation"},{"issue":"9493","key":"10.1016\/j.ijcard.2016.09.075_bb0255","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0260","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.mcna.2011.11.004","article-title":"Statins personalized","volume":"96","author":"Superko","year":"2012","journal-title":"Med. Clin. N. Am."},{"issue":"16","key":"10.1016\/j.ijcard.2016.09.075_bb0265","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1161\/CIRCULATIONAHA.112.101782","article-title":"Reducing residual risk in secondary prevention of cardiovascular disease","volume":"125","author":"Stone","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0270","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0275","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","article-title":"How do we improve patient compliance and adherence to long-term statin therapy?","volume":"15","author":"Maningat","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0280","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clinthera.2011.12.011","article-title":"Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis","volume":"34","author":"Degli Esposti","year":"2012","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0285","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/eurheartj\/ehl391","article-title":"Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study","volume":"28","author":"Penning-van Beest","year":"2007","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.075_bb0290","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/MLR.0b013e3181c132ad","article-title":"Patient, physician, and payment predictors of statin adherence","volume":"48","author":"Chan","year":"2010","journal-title":"Med. Care"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0295","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0300","first-page":"984","article-title":"Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service","volume":"46","author":"Markovic","year":"2005","journal-title":"Croat. Med. J."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0305","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5603\/CJ.a2014.0066","article-title":"Secondary prevention of coronary artery disease in contemporary clinical practice","volume":"22","author":"Jankowski","year":"2015","journal-title":"Cardiol. J."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2296-10-48","article-title":"Improving the physician\u2013patient cardiovascular risk dialogue to improve statin adherence","volume":"10","author":"Casebeer","year":"2009","journal-title":"BMC Fam. Pract."},{"issue":"8","key":"10.1016\/j.ijcard.2016.09.075_bb0315","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00406.2014","article-title":"The impact of statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects","volume":"309","author":"Izadpanah","year":"2015","journal-title":"Am. J. Phys. Cell Physiol."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0320","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12916-015-0459-4","article-title":"Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies","volume":"13","author":"Banach","year":"2015","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0325","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ab.2010.11.023","article-title":"Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling","volume":"410","author":"Aranibar","year":"2011","journal-title":"Anal. Biochem."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0330","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF03256413","article-title":"Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy","volume":"15","author":"Skottheim","year":"2011","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0335","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tox.2015.01.005","article-title":"Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity","volume":"329","author":"Gee","year":"2015","journal-title":"Toxicology"},{"issue":"8","key":"10.1016\/j.ijcard.2016.09.075_bb0340","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.revmed.2013.06.009","article-title":"Immune-mediated necrotizing myopathy associated with antibodies to hydroxy-methyl-glutaryl-coenzyme A reductase","volume":"35","author":"Hinschberger","year":"2014","journal-title":"Rev. Med. Interne"},{"issue":"7","key":"10.1016\/j.ijcard.2016.09.075_bb0345","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1586\/14779072.6.7.955","article-title":"Clinical characterization and molecular mechanisms of statin myopathy","volume":"6","author":"Toth","year":"2008","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0350","doi-asserted-by":"crossref","first-page":"870","DOI":"10.5551\/jat.2048","article-title":"Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment","volume":"16","author":"Hattori","year":"2009","journal-title":"J. Atheroscler. Thromb."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0355","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCGENETICS.113.000395","article-title":"CKM and LILRB5 are associated with serum levels of creatine kinase","volume":"7","author":"Dube","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.075_bb0360","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J. Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.075_bb0365","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","article-title":"Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education","volume":"7","author":"Wei","year":"2013","journal-title":"J. Clin. Lipidol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0370","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2014 the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0375","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"issue":"8A","key":"10.1016\/j.ijcard.2016.09.075_bb0380","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data \u2014 2005","volume":"97","author":"Bays","year":"2006","journal-title":"Am. J. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.075_bb0385","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.ijcard.2016.09.075_bb0390","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/0003-4819-137-7-200210010-00015","article-title":"Can statins cause chronic low-grade myopathy?","volume":"137","author":"Grundy","year":"2002","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0395","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2016.09.075_bb0400","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.2337\/dcS13-2038","article-title":"Intolerance to statins: mechanisms and management","volume":"36","author":"Bitzur","year":"2013","journal-title":"Diabetes Care"},{"issue":"9326","key":"10.1016\/j.ijcard.2016.09.075_bb0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"8A","key":"10.1016\/j.ijcard.2016.09.075_bb0410","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"National Lipid Association Statin Safety Assessment Task F. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.ijcard.2016.09.075_bb0415","doi-asserted-by":"crossref","first-page":"20607","DOI":"10.3390\/ijms151120607","article-title":"Molecular mechanisms underlying the effects of statins in the central nervous system","volume":"15","author":"McFarland","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0420","doi-asserted-by":"crossref","first-page":"d7622","DOI":"10.1136\/bmj.d7622","article-title":"Timing of onset of cognitive decline: results from Whitehall II prospective cohort study","volume":"344","author":"Singh-Manoux","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0425","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00415-009-5271-7","article-title":"Pravastatin and cognitive function in the elderly. Results of the PROSPER study","volume":"257","author":"Trompet","year":"2010","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.ijcard.2016.09.075_bb0430","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2013.07.013","article-title":"Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects","volume":"88","author":"Swiger","year":"2013","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.075_bb0435","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","article-title":"Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Ott","year":"2015","journal-title":"J. Gen. Intern. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2016.03.004","article-title":"Statin intolerance in a referral lipid clinic","volume":"10","author":"Lakey","year":"2016","journal-title":"J. Clin. Lipidol"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr. Atheroscler. Rep."},{"issue":"9500","key":"10.1016\/j.ijcard.2016.09.075_bb0450","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ijcard.2016.09.075_bb0455","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ijcard.2016.09.075_bb0460","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ijcard.2016.09.075_bb0465","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0470","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ahj.2015.09.007","article-title":"Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial","volume":"170","author":"Nicholls","year":"2015","journal-title":"Am. Heart J."},{"issue":"24","key":"10.1016\/j.ijcard.2016.09.075_bb0475","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Investigators","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.075_bb0480","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Group","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ijcard.2016.09.075_bb0485","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.2174\/1381612811319170020","article-title":"The role of fibrate treatment in dyslipidemia: an overview","volume":"19","author":"Katsiki","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0490","series-title":"Combination Therapy in Dyslipidemia","first-page":"11","article-title":"Statins and fibrates: should they be recommended?","author":"Chruschiel","year":"2015"},{"issue":"17","key":"10.1016\/j.ijcard.2016.09.075_bb0495","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides and Impact on Global Health Outcomes)","volume":"62","author":"Guyton","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"10.1016\/j.ijcard.2016.09.075_bb0500","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ijcard.2016.09.075_bb0505","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.102.16.1893","article-title":"Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.075_bb0510","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.ijcard.2016.09.075_bb0515","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.075_bb0520","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies","volume":"28","author":"Kastelein","year":"2014","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.075_bb0525","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1517\/14656566.2016.1118055","article-title":"Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options","volume":"17","author":"Serban","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0530","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5339\/gcsp.2015.20","article-title":"OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events","volume":"2015","author":"Hassan","year":"2015","journal-title":"Glob. Cardiol. Sci. Pract."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0535","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1074248414539562","article-title":"Proprotein convertase subtilisin\/kexin 9 inhibitors: an emerging lipid-lowering therapy?","volume":"20","author":"Dragan","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"16","key":"10.1016\/j.ijcard.2016.09.075_bb0540","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ijcard.2016.09.075_bb0545","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0550","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am. Heart J."},{"issue":"19","key":"10.1016\/j.ijcard.2016.09.075_bb0555","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/j.ijcard.2016.09.075_bb0560","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/eurheartj\/ehv056","article-title":"Sweetless'n low LDL-C targets for PCSK9 treatment","volume":"36","author":"Gencer","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0565","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12916-015-0503-4","article-title":"PCSK9 inhibition: the way forward in the treatment of dyslipidemia","volume":"13","author":"Stoekenbroek","year":"2015","journal-title":"BMC Med."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0570","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0000000000000239","article-title":"PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era","volume":"26","author":"Chapman","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"issue":"8","key":"10.1016\/j.ijcard.2016.09.075_bb0575","first-page":"436","article-title":"How do PCSK9 inhibitors stack up to statins for low-density lipoprotein cholesterol control?","volume":"8","author":"Zimmerman","year":"2015","journal-title":"Am. Health Drug Benefits"},{"issue":"10","key":"10.1016\/j.ijcard.2016.09.075_bb0580","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","article-title":"Lipid lowering with PCSK9 inhibitors","volume":"11","author":"Dadu","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"issue":"11","key":"10.1016\/j.ijcard.2016.09.075_bb0595","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jacc.2009.10.042","article-title":"Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia","volume":"55","author":"Avis","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0600","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.09.075_bb0605","series-title":"75th Annual Scientific Sessions of the American Diabetes Association Boston, MA, United States","article-title":"Efficacy and safety of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes","author":"Sattar","year":"2015"},{"key":"10.1016\/j.ijcard.2016.09.075_bb0610","series-title":"51st EASD Annual Meeting; Stockholm, Sweden","article-title":"Should we worry about raised triglycerides: the controversy continues","author":"Preiss","year":"2015"},{"key":"10.1016\/j.ijcard.2016.09.075_bb0615","series-title":"51st EASD Annual Meeting; Stockholm, Sweden","article-title":"Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4802 subjects with, at high risk for, or at low risk for, diabetes mellitus","author":"Sattar","year":"2015"},{"key":"10.1016\/j.ijcard.2016.09.075_bb0620","series-title":"51st EASD Annual Meeting; Stockholm, Sweden","article-title":"Efficacy and safety of alirocumab in individuals with diabetes: analyses from the ODYSSEY LONG TERM study","author":"Colhoun","year":"2015"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0625","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0630","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.M033969","article-title":"PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population","volume":"54","author":"Postmus","year":"2013","journal-title":"J. Lipid Res."},{"issue":"9","key":"10.1016\/j.ijcard.2016.09.075_bb0635","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.075_bb0640","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.clinthera.2015.09.004","article-title":"Non-statin treatments for managing LDL cholesterol and their outcomes","volume":"37","author":"Turner","year":"2015","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0645","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.atherosclerosis.2014.10.099","article-title":"ETC-1002: a future option for lipid disorders?","volume":"237","author":"Nikolic","year":"2014","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0650","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1378\/chest.08-0943","article-title":"Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports","volume":"134","author":"Fernandez","year":"2008","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.ijcard.2016.09.075_bb0655","first-page":"497","article-title":"Statin adverse effects: sorting out the evidence","volume":"63","author":"Mlodinow","year":"2014","journal-title":"J. Fam. Pract."},{"issue":"7058","key":"10.1016\/j.ijcard.2016.09.075_bb0660","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/bmj.313.7058.649","article-title":"Serum cholesterol concentration and death from suicide in men: Paris prospective study I","volume":"313","author":"Zureik","year":"1996","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0665","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/jwh.2007.0379","article-title":"Lipid-lowering medication use and aggression scores in women: a report from the NHLBI-sponsored WISE study","volume":"17","author":"Olson","year":"2008","journal-title":"J. Women's Health (Larchmt)"},{"issue":"1\u20132","key":"10.1016\/j.ijcard.2016.09.075_bb0670","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jns.2014.11.013","article-title":"Statin use increases the risk of depressive disorder in stroke patients: a population-based study","volume":"348","author":"Kang","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0675","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0680","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/qjmed\/hch035","article-title":"Severe irritability associated with statin cholesterol-lowering drugs","volume":"97","author":"Golomb","year":"2004","journal-title":"QJM"},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.075_bb0685","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/0002018-200831120-00007","article-title":"Statin-associated psychiatric adverse events: a case\/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting","volume":"31","author":"Tuccori","year":"2008","journal-title":"Drug Saf."},{"issue":"10","key":"10.1016\/j.ijcard.2016.09.075_bb0690","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1345\/aph.10366","article-title":"Nightmares and sleep disturbances with simvastatin and metoprolol","volume":"35","author":"Boriani","year":"2001","journal-title":"Ann. Pharmacother."},{"issue":"9716","key":"10.1016\/j.ijcard.2016.09.075_bb0695","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ijcard.2016.09.075_bb0700","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"9841","key":"10.1016\/j.ijcard.2016.09.075_bb0705","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2016.09.075_bb0710","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0715","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bjornsson","year":"2012","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0720","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0002-9343(02)01135-X","article-title":"Alopecia associated with atorvastatin","volume":"113","author":"Segal","year":"2002","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0725","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1440-0960.2006.00225.x","article-title":"Pravastatin-induced lichenoid drug eruption","volume":"47","author":"Pua","year":"2006","journal-title":"Australas. J. Dermatol."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.075_bb0730","first-page":"148","article-title":"Dermographism: an adverse effect of atorvastatin","volume":"14","author":"Adcock","year":"2001","journal-title":"J. Am. Board Fam. Pract."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0735","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1034\/j.1398-9995.2002.1n3628.x","article-title":"Chronic urticaria to atorvastatin","volume":"57","author":"Anliker","year":"2002","journal-title":"Allergy"},{"issue":"20","key":"10.1016\/j.ijcard.2016.09.075_bb0740","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1001\/jama.279.20.1613-a","article-title":"Toxic epidermal necrolysis from atorvastatin","volume":"279","author":"Pfeiffer","year":"1998","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0745","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000247363","article-title":"Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors","volume":"186","author":"Krasovec","year":"1993","journal-title":"Dermatology"},{"issue":"11","key":"10.1016\/j.ijcard.2016.09.075_bb0750","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jamaophthalmol.2013.4575","article-title":"Association of statin use with cataracts: a propensity score-matched analysis","volume":"131","author":"Leuschen","year":"2013","journal-title":"JAMA Ophthalmol."},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.075_bb0755","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ophtha.2008.08.006","article-title":"Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use","volume":"115","author":"Fraunfelder","year":"2008","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.075_bb0760","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1053\/j.ajkd.2003.12.023","article-title":"Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study","volume":"43","author":"Athyros","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0765","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","article-title":"Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database","volume":"340","author":"Hippisley-Cox","year":"2010","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.ijcard.2016.09.075_bb0770","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9965","key":"10.1016\/j.ijcard.2016.09.075_bb0775","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"9965","key":"10.1016\/j.ijcard.2016.09.075_bb0780","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ijcard.2016.09.075_bb0785","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.115.307071","article-title":"Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study","volume":"117","author":"Blom","year":"2015","journal-title":"Circ. Res."},{"issue":"18","key":"10.1016\/j.ijcard.2016.09.075_bb0790","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ijcard.2016.09.075_bb0795","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0800","series-title":"17th International Symposium on Atherosclerosis; Amsterdam, The Netherlands","article-title":"Long-term treatment with evolocumab in patients with homozygous familial hypercholesterolaemia (HoFH): interim results from the trial assessing long-term use of PCSK9 inhibition in subjects with genetic LDL disorder (TAUSSIG) study. [Abstract No. 255]","author":"Raal","year":"2015"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.075_bb0805","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","article-title":"A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk","volume":"117","author":"Kiyosue","year":"2016","journal-title":"Am. J. Cardiol."},{"issue":"43","key":"10.1016\/j.ijcard.2016.09.075_bb0810","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0815","first-page":"2119","article-title":"ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia","volume":"130","author":"Ginsberg","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ijcard.2016.09.075_bb0820","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0825","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.075_bb0830","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacl.2014.09.007","article-title":"Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial","volume":"8","author":"Moriarty","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijcard.2016.09.075_bb0835","series-title":"17th International Symposium on Atherosclerosis; Amsterdam, The Netherlands","article-title":"Phase 3 randomized trial evaluating alirocumab every four weeks dosing as add-on to statin or as monotherapy: ODYSSEY CHOICE I [Abstract No. 0254]","author":"Roth","year":"2015"},{"key":"10.1016\/j.ijcard.2016.09.075_bb0840","series-title":"17th International Symposium on Atherosclerosis; Amsterdam, The Netherlands","article-title":"Alirocumab in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study [Abstract No. 0269]","author":"Stroes","year":"2015"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316324834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316324834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T03:21:23Z","timestamp":1692501683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316324834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":166,"alternative-id":["S0167527316324834"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.09.075","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.09.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}